Contact information
Research groups
Colleges
Young-Eun Park
PhD
Postdoctoral Scientist
Research Interests:
My research focuses on cancer immunotherapy, with a particular interest in how the tumour microenvironment shapes anti-tumour immune responses and influences the efficacy of cancer vaccines. I investigate the cellular and molecular mechanisms governing interactions between tumour cells, stromal cells, and immune cells to identify strategies that enhance vaccine-induced cytotoxic T-cell responses. By integrating tumour biology with immunology, I aim to contribute to the development of more effective cancer vaccines and combination immunotherapies.
Background:
I am a Postdoctoral Research Scientist in the Cancer Vaccine Lab at the University of Oxford, where I investigate cancer immunotherapy and the development of next-generation cancer vaccines. As part of the GO-PRECIsE team, I work in collaboration with GSK to investigate innovative immunotherapeutic strategies and accelerate the translation of cancer vaccine research into clinical applications.
I obtained my PhD from the University of Auckland, New Zealand, where my research focused on bone regeneration, investigating how hormones regulate bone cell function and how biomaterials can enhance bone repair.
Following my PhD, I joined the Bone Oncology Group at the University of Oxford, led by Professor Claire Edwards, where I studied multiple myeloma, a haematological malignancy of the bone marrow. My research focused on the interactions between tumour cells and the bone marrow microenvironment, particularly the role of bone marrow adipocytes in regulating myeloma dormancy and disease progression through cellular and molecular mechanisms.
Building on my expertise in tumour biology and the tumour microenvironment, I joined the Cancer Vaccine Lab to investigate how the tumour microenvironment influences anti-tumour immunity and the effectiveness of cancer vaccines. My long-term research goal is to advance the development of more effective cancer immunotherapies by integrating insights into tumour biology, the immune microenvironment, and vaccine design.